EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Psychosis, Catatonia and Tachypnoea Following Paliperidone Palmitate 3‐Monthly Injection Error: Case Report

Milla R McLean iD, Lee Hanley iD, M J Yoo iD

Case Reports in Psychiatry · 2026-01 · 2026 (1)

DOI: 10.1155/crps/4635562 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Psychiatry, online erschienen am 18.08.2026. Verfasst von Milla R McLean und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, The Royal Melbourne Hospital, Melbourne, Victoria, Australia, thermh.org.au. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Melbourne.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Paliperidone palmitate 3‐monthly (PP3M) is a long‐acting Injection (LAI) formulation of the anti‐psychotic medication paliperidone, also known as 9‐hydroxyrisperidone (9‐OH‐RIS). There is a notable absence of clinical guidelines or case reports pertaining to PP3M overdose and management of incorrect dosing. Patient Concerns and Clinical Findings We present the first reported case of PP3M administered at 1 monthly intervals for three consecutive months in the community setting and describe the inpatient management of psychosis and catatonia occurring in the context of this overdose. Diagnoses, Interventions and Outcomes During this patient’s admission to an inpatient psychiatric unit, our team, involving specialised pharmacy, navigated the acute management of psychosis in the context of PP3M overdose in the absence of published guidelines. We share the use of electroconvulsive therapy (ECT) and oral lorazepam in managing this patient’s acute psychosis and catatonia presentation and provide a rationale for the timing of safe recommencement of paliperidone oral medication. The patient was safely discharged home.

Conclusions

We highlight the need for LAI overdose guidelines as an important area for review and development of clinical guidelines as we see increasing use of paliperidone palmitate 1‐monthly (PP1M), PP3M, and paliperidone palmitate 6‐monthly injection (PP6M) in the community.

Schlagwörter

Stichwörter der Autor:innen

anti-psychoticcase reportlong-acting injectionmedication errorpaliperidone palmitate

Autor:innen und Institutionen

  • Department of Psychiatry, The Royal Melbourne Hospital, Melbourne, Victoria, Australia, thermh.org.au.
  • Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Australia, unimelb.edu.au.
  • Department of Psychiatry, Melbourne Medical School, The University of Melbourne, Melbourne, Australia, unimelb.edu.au.

ORCID-Profile: Milla R McLean, Lee Hanley, M J Yoo

Förderung

  • University of Melbourne

Zitieren

APA

McLean, M. R., Hanley, L., & Yoo, M. J. (2026). Psychosis, Catatonia and Tachypnoea Following Paliperidone Palmitate 3‐Monthly Injection Error: Case Report. Case Reports in Psychiatry, 2026(1). https://doi.org/10.1155/crps/4635562

Vancouver

McLean MR, Hanley L, Yoo MJ. Psychosis, Catatonia and Tachypnoea Following Paliperidone Palmitate 3‐Monthly Injection Error: Case Report. Case Reports in Psychiatry. 2026;2026(1). doi:10.1155/crps/4635562

BibTeX
@article{McLean2026,
  author = {McLean, Milla R and Hanley, Lee and Yoo, M J},
  title = {Psychosis, Catatonia and Tachypnoea Following Paliperidone Palmitate 3‐Monthly Injection Error: Case Report},
  journal = {Case Reports in Psychiatry},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/crps/4635562}
}
Kostenlos starten →